313 related articles for article (PubMed ID: 32125100)
1. Analysis of the clinical response and changes in the expression of TNF-α and its TNFR1 and TNFR2 receptors in patients with psoriasis vulgaris treated with ustekinumab.
Wcisło-Dziadecka DL; Grabarek B; Kruszniewska-Rajs C; Gola JM; Simka K; Mazurek U
Adv Clin Exp Med; 2020 Feb; 29(2):235-241. PubMed ID: 32125100
[TBL] [Abstract][Full Text] [Related]
2. The analysis of the therapeutic potential of ustekinumab in psoriasis vulgaris treatment.
Wcisło-Dziadecka D; Grabarek B; Kruszniewska-Rajs C; Strzałka-Mrozik B
Dermatol Ther; 2019 May; 32(3):e12843. PubMed ID: 30693647
[TBL] [Abstract][Full Text] [Related]
3. TNFR2 Depletion Reduces Psoriatic Inflammation in Mice by Downregulating Specific Dendritic Cell Populations in Lymph Nodes and Inhibiting IL-23/IL-17 Pathways.
Chandrasekharan UM; Kaur R; Harvey JE; Braley C; Rai V; Lee M; de Windt N; Hsieh J; Jaini R; Bayik D; Scheraga RG; Fernandez AP; DiCorleto PE; Husni ME
J Invest Dermatol; 2022 Aug; 142(8):2159-2172.e9. PubMed ID: 35090950
[TBL] [Abstract][Full Text] [Related]
4. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
Takahashi N; Noda S; Taniguchi T; Adachi M
Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
[TBL] [Abstract][Full Text] [Related]
5. Behavior of tumor necrosis factor-α and tumor necrosis factor receptor 1/tumor necrosis factor receptor 2 system in mononuclear cells recovered from peritoneal fluid of women with endometriosis at different stages.
Salmeri FM; Laganà AS; Sofo V; Triolo O; Sturlese E; Retto G; Pizzo A; D'Ascola A; Campo S
Reprod Sci; 2015 Feb; 22(2):165-72. PubMed ID: 24844917
[TBL] [Abstract][Full Text] [Related]
6. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.
Onsun N; Akaslan TÇ; Sallahoglu K; Gülcan AS; Bulut H; Yabacı A
J Dermatolog Treat; 2022 May; 33(3):1727-1732. PubMed ID: 33704001
[TBL] [Abstract][Full Text] [Related]
7. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
[TBL] [Abstract][Full Text] [Related]
8. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris.
Clemmensen A; Spon M; Skov L; Zachariae C; Gniadecki R
J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1037-40. PubMed ID: 21108668
[TBL] [Abstract][Full Text] [Related]
9. Differential role of TNFR1 and TNFR2 in the development of imiquimod-induced mouse psoriasis.
Chen S; Lin Z; Xi L; Zheng Y; Zhou Q; Chen X
J Leukoc Biol; 2021 Dec; 110(6):1047-1055. PubMed ID: 34494306
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
11. Lack of Evidence for a Direct Interaction of Progranulin and Tumor Necrosis Factor Receptor-1 and Tumor Necrosis Factor Receptor-2 From Cellular Binding Studies.
Lang I; Füllsack S; Wajant H
Front Immunol; 2018; 9():793. PubMed ID: 29740434
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
Stull DE; Griffiths CEM; Gilloteau I; Zhao Y; Guana A; Finlay AY; Sherif B; Houghton K; Puig L
Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
[TBL] [Abstract][Full Text] [Related]
13. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
[TBL] [Abstract][Full Text] [Related]
14. [Expression of tumor necrosis factor-alpha (TNF-alpha) on peritoneal fluid mononuclear cells in women with endometriosis].
Gogacz M; Bogusiewicz M; Putowski L; Adamiak A; Wertel I; Jakowicki JA; Rechberger T
Ginekol Pol; 2008 Jan; 79(1):31-5. PubMed ID: 18510047
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
[TBL] [Abstract][Full Text] [Related]
17. TNF-
Gane JM; Stockley RA; Sapey E
J Immunol Res; 2016; 2016():1079851. PubMed ID: 27747245
[TBL] [Abstract][Full Text] [Related]
18. Regulation of myocardial stromal cell-derived factor 1α/CXCL12 by tumor necrosis factor signaling.
Wang M; Wang L; Huang C; Wang IW; Turrentine MW
J Surg Res; 2017 Jan; 207():155-163. PubMed ID: 27979472
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
Lebwohl M; Papp K; Han C; Schenkel B; Yeilding N; Wang Y; Krueger GG
Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
